Canadian pharmacy and therapeutics news: recalls, shortages, guideline updates and developments in practice.
OCP has clarified how incident reports support shared learning and who can access them. Ontario pharmacies should prepare for the January 1, 2027 platform requirements.
Sep 8, 2026 · 1 min read Read briefing
ISMP Canada’s July bulletin examines medication incidents linked to a return to hospital. It identifies practical safeguards for hospital and community pharmacy teams.
Sep 8, 2026 · 1 min read Read briefingHealth Canada has completed a safety review linking GLP-1 receptor agonists — including semaglutide, tirzepatide, dulaglutide, liraglutide, and lixisenatide — to an increased risk of pulmonary aspiration during general anesthesia or deep sedation, and has updated the Canadian product monographs for the entire drug class. Community and hospital pharmacists are often the last clinician to see both the medication history and the upcoming procedure.
Apr 30, 2026 · 3 min read Read briefing
A consumer nearly swallowed a boric acid vaginal suppository after mistaking the oral-look capsule for a vitamin, prompting ISMP Canada and manufacturer Szio+ Inc. to add explicit vaginal-use warnings to the Utiva Yeast Control packaging. Pharmacists selling this and similar non-prescription boric acid products need to counsel proactively, since these are self-selected products often sold without a pharmacist consult.
Feb 26, 2026 · 3 min read Read briefing
Health Canada and Marcan Pharmaceuticals recalled two lots of MAR-Amlodipine 5 mg after some bottles were found to contain midodrine 2.5 mg tablets instead, a mix-up that could send a hypertensive patient's blood pressure dangerously higher or a hypotensive patient's dangerously lower. Community pharmacists need the exact lot numbers and tablet-appearance cues to check remaining stock and dispensed bottles.
Feb 7, 2026 · 2 min read Read briefing